Propanc Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 13, 2018 and accepted by EDGAR at Nov 9, 2018, 18:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2018-07-01 to 2018-09-30 | $8.1k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2018-07-01 to 2018-09-30 | $56.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$448.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-07-01 to 2018-09-30 | $624.5k | us-gaap:InterestExpense |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$2.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2018-07-01 to 2018-09-30 | −$419.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-09-30 | $38.9k | us-gaap:Cash |
| Current assets | At period end2018-09-30 | $73.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $82.8k | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $5.6m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2018-09-30 | $3.8m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2018-09-30 | −$5.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-18-015599. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.